Cargando…

S3-Leitlinie Depressive Störungen im Kindes- und Jugendalter: Wo geht es hin?

The German guideline for the treatment of depressive disorders in children and adolescents was first published in July 2013. Currently, this guideline is undergoing revision, in which the recommendations of the original version of the guideline are revisited and updated. This report aims to give an...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulte-Körne, Gerd, Klingele, Cosima, Zsigo, Carolin, Kloek, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328849/
https://www.ncbi.nlm.nih.gov/pubmed/37227472
http://dx.doi.org/10.1007/s00103-023-03721-4
_version_ 1785069893357404160
author Schulte-Körne, Gerd
Klingele, Cosima
Zsigo, Carolin
Kloek, Maria
author_facet Schulte-Körne, Gerd
Klingele, Cosima
Zsigo, Carolin
Kloek, Maria
author_sort Schulte-Körne, Gerd
collection PubMed
description The German guideline for the treatment of depressive disorders in children and adolescents was first published in July 2013. Currently, this guideline is undergoing revision, in which the recommendations of the original version of the guideline are revisited and updated. This report aims to give an overview of the current status and the next steps for this revision. As part of the revision process, the key questions posited in the original version were expanded upon. In this, new questions were added regarding complementary therapies, that is, therapies meant to be administered in addition to the usual treatment, as well as regarding the transitionary period from adolescence into adulthood. For all key questions, new systematic literature searches were conducted in order to update the relevant evidence. For this, randomized controlled studies, systematic reviews, and non-controlled intervention studies were included and rated according to their relevance as well as possible risks of bias. Thus, all studies could be assigned a level of evidence that takes into account both the quality and the importance of the study to the guideline. This report will give a brief overview of the most important insights resulting from the new evidence base identified for the revision. While insights regarding psychotherapy are largely unchanged, there are changes in the evidence for certain antidepressants. In the field of complementary therapies, new evidence has been found for physical activity. In general, it is likely that most recommendations of the original guideline regarding first- and second-line treatments will be updated. The completion of the revision and the publishing of the revised guideline are expected to take until the end of 2023.
format Online
Article
Text
id pubmed-10328849
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103288492023-07-09 S3-Leitlinie Depressive Störungen im Kindes- und Jugendalter: Wo geht es hin? Schulte-Körne, Gerd Klingele, Cosima Zsigo, Carolin Kloek, Maria Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Leitthema The German guideline for the treatment of depressive disorders in children and adolescents was first published in July 2013. Currently, this guideline is undergoing revision, in which the recommendations of the original version of the guideline are revisited and updated. This report aims to give an overview of the current status and the next steps for this revision. As part of the revision process, the key questions posited in the original version were expanded upon. In this, new questions were added regarding complementary therapies, that is, therapies meant to be administered in addition to the usual treatment, as well as regarding the transitionary period from adolescence into adulthood. For all key questions, new systematic literature searches were conducted in order to update the relevant evidence. For this, randomized controlled studies, systematic reviews, and non-controlled intervention studies were included and rated according to their relevance as well as possible risks of bias. Thus, all studies could be assigned a level of evidence that takes into account both the quality and the importance of the study to the guideline. This report will give a brief overview of the most important insights resulting from the new evidence base identified for the revision. While insights regarding psychotherapy are largely unchanged, there are changes in the evidence for certain antidepressants. In the field of complementary therapies, new evidence has been found for physical activity. In general, it is likely that most recommendations of the original guideline regarding first- and second-line treatments will be updated. The completion of the revision and the publishing of the revised guideline are expected to take until the end of 2023. Springer Berlin Heidelberg 2023-05-25 2023 /pmc/articles/PMC10328849/ /pubmed/37227472 http://dx.doi.org/10.1007/s00103-023-03721-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Leitthema
Schulte-Körne, Gerd
Klingele, Cosima
Zsigo, Carolin
Kloek, Maria
S3-Leitlinie Depressive Störungen im Kindes- und Jugendalter: Wo geht es hin?
title S3-Leitlinie Depressive Störungen im Kindes- und Jugendalter: Wo geht es hin?
title_full S3-Leitlinie Depressive Störungen im Kindes- und Jugendalter: Wo geht es hin?
title_fullStr S3-Leitlinie Depressive Störungen im Kindes- und Jugendalter: Wo geht es hin?
title_full_unstemmed S3-Leitlinie Depressive Störungen im Kindes- und Jugendalter: Wo geht es hin?
title_short S3-Leitlinie Depressive Störungen im Kindes- und Jugendalter: Wo geht es hin?
title_sort s3-leitlinie depressive störungen im kindes- und jugendalter: wo geht es hin?
topic Leitthema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328849/
https://www.ncbi.nlm.nih.gov/pubmed/37227472
http://dx.doi.org/10.1007/s00103-023-03721-4
work_keys_str_mv AT schultekornegerd s3leitliniedepressivestorungenimkindesundjugendalterwogehteshin
AT klingelecosima s3leitliniedepressivestorungenimkindesundjugendalterwogehteshin
AT zsigocarolin s3leitliniedepressivestorungenimkindesundjugendalterwogehteshin
AT kloekmaria s3leitliniedepressivestorungenimkindesundjugendalterwogehteshin